These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11287079)

  • 21. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
    Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
    Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
    Truong L; Allbutt H; Kassiou M; Henderson JM
    Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
    Yoshimura N; Kuno S; Chancellor MB; De Groat WC; Seki S
    Br J Pharmacol; 2003 Aug; 139(8):1425-32. PubMed ID: 12922929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.
    Smith MP; Fletcher-Turner A; Yurek DM; Cass WA
    Neurochem Res; 2006 Apr; 31(4):533-9. PubMed ID: 16758362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease.
    Willis GL; Kennedy GA
    Rev Neurosci; 2004; 15(1):75-87. PubMed ID: 15046200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson's disease.
    Steiner B; Winter C; Hosman K; Siebert E; Kempermann G; Petrus DS; Kupsch A
    Exp Neurol; 2006 Jun; 199(2):291-300. PubMed ID: 16360152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
    Srinivasan J; Schmidt WJ
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):629-38. PubMed ID: 15118809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
    Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
    Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed-ratio discrimination training as replacement therapy in Parkinson's disease: studies in a 6-hydroxydopamine-treated rat model.
    Van Keuren KR; Stodgell CJ; Schroeder SR; Tessel RE
    Brain Res; 1998 Jan; 780(1):56-66. PubMed ID: 9473587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental models and behavioural tests used in the study of Parkinson's disease.
    Mokrý J
    Physiol Res; 1995; 44(3):143-50. PubMed ID: 8869270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
    Moore AE; Cicchetti F; Hennen J; Isacson O
    Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease.
    Cass WA; Peters LE; Smith MP
    Brain Res; 2005 Feb; 1034(1-2):153-61. PubMed ID: 15713267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
    Cerri S; Greco R; Levandis G; Ghezzi C; Mangione AS; Fuzzati-Armentero MT; Bonizzi A; Avanzini MA; Maccario R; Blandini F
    Stem Cells Transl Med; 2015 Sep; 4(9):1073-85. PubMed ID: 26198165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
    Cheng L; Chen L; Wei X; Wang Y; Ren Z; Zeng S; Zhang X; Wen H; Gao C; Liu H
    J Neuroinflammation; 2018 Aug; 15(1):243. PubMed ID: 30157869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
    Kirik D; Georgievska B; Rosenblad C; Björklund A
    Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.